Cytotoxic T-Cells Drive Outcome in Inflammatory Dilated Cardiomyopathy

Affiliations

• ¹ Department of Cardiology, Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, the Netherlands. (M.A.S., M.T.H.M.H., S.L.V.M.S., M.F.G.H.M.V., B.N., R.E.W.v.L., C.K., H.-P.B.-L.R., V.P.M.v.E., J.A.J.V., S.R.B.H.).
• ² William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, United Kingdom. (D.H., S.F., F.M.M.-B.).
• ³ Barts Heart Centre, Barts Health NHS Trust, St Bartholomew's Hospital, London, United Kingdom (D.H., F.M.M.-B.).
• ⁴ Department of Pathology, Maastricht University Medical Center, the Netherlands. (M.T.H.M.H., X.L.).
• ⁵ Netherlands Heart Institute, Utrecht, the Netherlands (M.T.H.M.H.).
• ⁶ Department of Clinical Genetics, Maastricht University Medical Center, the Netherlands. (S.L.V.M.S., J.A.J.V.).
• ⁷ European Reference Network for Rare, Low Prevalence and Complex Diseases of the Heart (ERN GUARD-Heart) (S.L.V.M.S., J.A.J.V., S.R.B.H.).
• ⁸ Department of Cardiovascular Sciences, Centre for Molecular and Vascular Biology, Herestraat 49, University of Leuven, Belgium (S.L.V.M.S., S.R.B.H.).
• ⁹ Division Clinical and Experimental Immunology, Department of Internal Medicine, Maastricht University Medical Center, the Netherlands. (P.v.P.).
• ¹⁰ Centre for Inflammation and Therapeutic Innovation, Queen Mary University of London, United Kingdom. (F.M.M.-B.).